Employment of the CAR-TEAM combination resulted in increased recruitment and directed killing of bystander effector T cells against GBM tumor cells, promotion of the effector memory T cell phenotype, decreased expression of surface exhaustion markers, and effective killing of multiple EGFRvIII-EGFR+ and EGFvIII+ glioma models and patient-derived xenografts [188,189]. The gene discussed is EGFR; the disease is neoplasm.